Gut Microbiota Are More Strongly Associated With Impairments in Health-Related Quality of Life Than Disease Activity in Inflammatory Bowel Disease.

Little, Robert D; Jayawardana, Thisun C; Zhang, Fan; Houshyar, Yashar; Koentgen, Sabrina; Wu, Nan; Ellepola, Anuk; Tavakoli, Paris et al. · Am J Gastroenterol · 2025

cross_sectional · Level IV

Where this comes from

Abstract

Inflammatory bowel disease (IBD) affects health-related quality of life (HRQoL). Gut dysbiosis in IBD is common and may contribute to this observation. The aims of this study were to measure HRQoL and its association with clinical and microbial features in patients with IBD and healthy controls (HCs). Fecal and oral samples, demographics, 36-item Short-Form Health Survey (SF-36), and 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32) surveys were collected at baseline from patients with Crohn's disease (CD), ulcerative colitis (UC) and HCs enrolled in The Australian IBD Microbiome Study. Samples underwent 16S rRNA sequencing. Associations between HRQoL variables and alpha diversity, beta diversity, and microbial taxa abundance were measured using R. A total of 751 participants (305 HCs, 232 CD, 214 UC) were included. HRQoL was lower in IBD participants compared with HCs using the SF-36 (physical component summary 51.6 vs 55.7, P < 0.0001 and mental component summary score 45.1 vs 52.2, P < 0.001). Despite high rates of remission, impaired IBD-HRQoL (IBDQ-32 score <170) was common in patients with CD (42%) and UC (41%). Patients with impaired IBDQ-32 scores demonstrated lower alpha diversity (Chao1 155.2 vs 172.4, P = 0.015) and distinct beta diversity ( R2 = 0.003, P = 0.019) compared with those with preserved IBD-HRQoL. Sixty-two genera were associated with at least one HRQoL measure in both patients with UC and patients with CD. The number and strength of associations between genera and HRQoL measures outweighed microbial associations with clinical and biochemical activity. Alterations in gut microbiota are associated with HRQoL outcomes in patients with IBD and HCs.